154 related articles for article (PubMed ID: 35073960)
1. Differential effects of radiation fractionation regimens on glioblastoma.
McKelvey KJ; Hudson AL; Donaghy H; Stoner SP; Wheeler HR; Diakos CI; Howell VM
Radiat Oncol; 2022 Jan; 17(1):17. PubMed ID: 35073960
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
3. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Pedretti S; Masini L; Turco E; Triggiani L; Krengli M; Meduri B; Pirtoli L; Borghetti P; Pegurri L; Riva N; Gatta R; Fusco V; Scoccianti S; Bruni A; Ricardi U; Santoni R; Magrini SM; Buglione M
J Neurooncol; 2019 Jul; 143(3):447-455. PubMed ID: 31054101
[TBL] [Abstract][Full Text] [Related]
5. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Perlow HK; Yaney A; Yang M; Klamer B; Matsui J; Raval RR; Blakaj DM; Arnett A; Beyer S; Elder JB; Ammirati M; Lonser R; Hardesty D; Ong S; Giglio P; Pillainayagam C; Goranovich J; Grecula J; Chakravarti A; Gondi V; Brown PD; Palmer JD
J Neurooncol; 2022 Jan; 156(2):399-406. PubMed ID: 35013838
[TBL] [Abstract][Full Text] [Related]
7. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial.
Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J
J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027
[TBL] [Abstract][Full Text] [Related]
8. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Arvold ND; Tanguturi SK; Aizer AA; Wen PY; Reardon DA; Lee EQ; Nayak L; Christianson LW; Horvath MC; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Alexander BM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):384-9. PubMed ID: 25841623
[TBL] [Abstract][Full Text] [Related]
11. Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Chidley P; Shanker M; Phillips C; Haghighi N; Pinkham MB; Whittle JR; Sia J
J Neurooncol; 2022 Nov; 160(2):361-374. PubMed ID: 36355260
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
13. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
[TBL] [Abstract][Full Text] [Related]
16. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
[TBL] [Abstract][Full Text] [Related]
17. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
Izzuddeen Y; Gupta S; Haresh KP; Sharma D; Giridhar P; Rath GK
J Neurooncol; 2020 Jan; 146(1):91-95. PubMed ID: 31728883
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
